ストックスクリーナーアプリを入手
138.78
0.21%
0.29
前日終値:
$138.49
開ける：
$139.44
24時間の取引高:
423.07K
Relative Volume:
0.52
時価総額：
$5.80B
収益：
当期純損益:
株価収益率:
-147.64
EPS:
-0.94
ネットキャッシュフロー:
1週間 パフォーマンス:
+27.53%
1か月 パフォーマンス:
+19.87%
6か月 パフォーマンス:
+100.40%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$134.49
$139.93
1週間の範囲:
$113.00
$141.75
52週間の値動き範囲:
$32.00
$141.75
Veradermics Inc Stock (MANE) Company Profile
Compare MANE vs VRTX, REGN, MRNA, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MANE
Veradermics Inc
|
138.78 | 5.80B | 0 | 0 | 0 | -0.94 |
VRTX
Vertex Pharmaceuticals Inc
|
523.93 | 132.80B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.02 | 82.88B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.10 | 79.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
873.71 | 54.94B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.63 | 42.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
Veradermics Inc Stock (MANE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-07-15 | 開始されました | B. Riley Securities | Buy |
| 2026-06-02 | 開始されました | Needham | Buy |
| 2026-03-02 | 開始されました | Cantor Fitzgerald | Overweight |
| 2026-03-02 | 開始されました | Citigroup | Buy |
| 2026-03-02 | 開始されました | Jefferies | Buy |
| 2026-03-02 | 開始されました | Leerink Partners | Outperform |
すべてを表示
Veradermics Inc (MANE) 最新ニュース
Could This Pill Be a Game Changer for Hair Loss? Veradermics Reports Major Breakthrough - Yahoo Finance
Veradermics (NYSE:MANE) Sets New 52-Week HighTime to Buy? - MarketBeat
Veradermics, Incorporated (MANE) Discusses Positive Top Line Results From Phase III Study 304 of VDPHL01 in Male Pattern Hair LossSlideshow (NYSE:MANE) 2026-10-21 - Seeking Alpha
Veradermics' oral hair-loss drug shown to boost hair growth in late-stage study - Reuters
MANE News Today | Why did Veradermics stock go up today? - MarketBeat
MANE Stock Grinds Higher As Bulls Defend Key Levels - StocksToTrade
MANE Stock Holds Gains As Volatility Draws Active Traders - Timothy Sykes
Why Is Veradermics Stock Soaring Monday?Veradermics (NYSE:MANE) - Benzinga
Veradermics’ stock up on male hair loss trial success - Yahoo Finance
Veradermics Soars 10% as Phase 3 Data Show Oral Hair-Loss Pill Could “Transform” Treatment - Yahoo Finance
Veradermics Phase III Hair Loss Trial Meets All Endpoints, Posts Strong Growth Results - Yahoo Finance
Veradermics Phase III Hair Loss Trial Meets All Endpoints, Posts Strong Growth Results - TradingView
Veradermics Phase III Hair Loss Trial Meets All Endpoints, Posts Strong Growth Results - TradingView
Veradermics (NYSE:MANE) Shares Gap Up Following Analyst Upgrade - MarketBeat
Silence Therapeutics, Disc Medicine, Veradermics And Other Big Stocks Moving Higher On Monday - Benzinga
Veradermics Scores Hair Loss Win as Biotech Bets on Baldness (1) - Bloomberg Law News
A 536-man trial compared Veradermics (MANE)'s experimental hair-loss drug with placebo. - Stock Titan
Veradermics stock surges as hair loss drug meets Phase 3 goals - Investing.com
Roche inks $15B ADC pact with Hansoh; Veradermics scores in another baldness study - Yahoo Finance
Veradermics reports phase 3 trial success for hair loss drug By Investing.com - Investing.com Nigeria
85% of men in a trial reported better coverage on a twice-daily hair-loss pill, versus 35.3% on placebo. - Stock Titan
Veradermics Scores Hair Loss Win as Biotech Bets on Baldness - Bloomberg
Veradermics’ oral Rogaine wins again at growing hair in late-stage trial - Endpoints News
Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 3 ‘304’ Clinical Trial in Male Pattern Hair Loss - Yahoo Finance
Veradermics to present phase 3 hair loss trial results Monday - Investing.com
Veradermics to Hold Conference Call to Discuss Topline Results from Phase 3 ‘304’ Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss - www.marketscreener.com
Veradermics, Incorporated (NYSE:MANE) Stock Has Consensus Price Target of $153.00 According to Brokerages - MarketBeat
JPMorgan Chase reports a passive stake above 5% in Veradermics (MANE). - Stock Titan
Veradermics: The Momentum Is Building, But Know This Before The H2 2026 Readouts (MANE) - Seeking Alpha
Veradermics (NYSE:MANE) Hits New 12-Month HighHere's What Happened - MarketBeat
MANE Stock Jumps As Traders Zero In On Momentum - StocksToTrade
MANE Stock Surges As Traders Target Volatile Breakout - Timothy Sykes
MANE Stock Surges As Traders Target Volatile Breakout - Timothy Sykes
MANE Stock Jumps On High Volume As Bulls Test Breakout - StocksToTrade
MANE Stock Jumps As Traders Pile Into Volatile Breakout - Timothy Sykes
MANE Stock Jumps As Traders Pile Into Volatile Breakout - Timothy Sykes
MANE Stock Pops On Volatile Rally As Traders Pile In - StocksToTrade
Veradermics (NYSE:MANE) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
Veradermics (NYSE:MANE) Aktienprognose & Analystenprognosen - Simply Wall Street
Veradermics (NYSE:MANE) Stock Forecast & Analyst Predictions - Simply Wall Street
Veradermics (NYSE:MANE) Stock Jumps 3.4%Time to Buy? - MarketBeat
Veradermics (NYSE:MANE) Stock Falls 8.1%Here's What Happened - MarketBeat
Top Veradermics (MANE) Competitors 2026 - MarketBeat
Veradermics (NYSE:MANE) Trading 6.1% HigherWhat's Next? - MarketBeat
Veradermics, Incorporated (NYSE:MANE) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Veradermics: Buy Before The Catalysts (NYSE:MANE) - Seeking Alpha
Baldness Drug Stocks like Veradermics (MANE) and Absci (ABSI) Are Chasing the Same Wall Street Magic as Ozempic - Yahoo Finance
Citi Keeps Their Buy Rating on Veradermics, Incorporated (MANE) - theglobeandmail.com
Veradermics at Cantor healthcare conference: hair-loss market in focus By Investing.com - Investing.com Canada
Veradermics at Cantor healthcare conference: hair-loss market in focus - Investing.com
Veradermics Inc (MANE) 財務データ
収益
当期純利益
現金流量
EPS
Veradermics Inc (MANE) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Averill Madison Master Fund, L | Affiliate |
Aug 19 '26 |
Proposed Sale |
107.25 |
59,399 |
6,370,543 |
0 |
| Averill Master Fund, Ltd. | Affiliate |
Aug 19 '26 |
Proposed Sale |
107.25 |
690,601 |
74,066,957 |
0 |
| Timothy Durso | Officer |
Aug 17 '26 |
Proposed Sale |
111.28 |
87,000 |
9,681,360 |
0 |
| Waldman Reid Alexander | Chief Executive Officer |
Aug 17 '26 |
Sale |
107.86 |
67,500 |
7,280,713 |
170,824 |
| Waldman Reid Alexander | Chief Executive Officer |
Aug 17 '26 |
Option Exercise |
12.19 |
3,452 |
42,080 |
238,324 |
| Durso Timothy August | Chief Technical Officer |
Aug 17 '26 |
Option Exercise |
12.19 |
3,452 |
42,080 |
121,642 |
| Durso Timothy August | Chief Technical Officer |
Aug 17 '26 |
Sale |
107.82 |
43,500 |
4,690,005 |
78,142 |
| Reid Alexander Waldman | CEO |
Aug 17 '26 |
Proposed Sale |
111.28 |
135,000 |
15,022,800 |
0 |
| CHILDS JOHN W | Director |
Aug 12 '26 |
Sale |
107.12 |
100,000 |
10,711,700 |
194,117 |
| AMZL, LP | Shareholder |
Aug 12 '26 |
Proposed Sale |
108.95 |
104,587 |
11,394,754 |
0 |
2.37%
2.16%
大文字化:
|
ボリューム (24 時間):